Autoantibodies targeting G protein-coupled receptors: An evolving history in autoimmunity. Report of the 4th international symposium

Otávio Cabral-Marques; Guido Moll; Rusan Catar; Beate Preuß; Lukas Bankamp; Ann Christin Pecher; Joerg Henes; Reinhild Klein; A. S. Kamalanathan; Reza Akbarzadeh; Wieke van Oostveen; Bettina Hohberger; Matthias Endres; Bryan Koolmoes; Nivine Levarht; Rudmer Postma; Vincent van Duinen; Anton Jan van Zonneveld; Jeska de Vries-Bouwstra; Cynthia Fehres; Florian Tran; Fernando Yuri Nery do Vale; Kamilla Batista da Silva Souza; Igor Salerno Filgueiras; Lena F. Schimke; Gabriela Crispim Baiocchi; Gustavo Cabral de Miranda; Dennyson Leandro Mathias da Fonseca; Paula Paccielli Freire; Alexander M. Hackel; Hanna Grasshoff; Anja Kerstein-Stähle; Antje Müller; Ralf Dechend; Xinhua Yu; Frank Petersen; Franziska Sotzny; Thomas P. Sakmar; Hans D. Ochs; Kai Schulze-Forster; Harald Heidecke; Carmen Scheibenbogen; Yehuda Shoenfeld; Gabriela Riemekasten

doi:10.1016/j.autrev.2023.103310

Autoantibodies targeting G protein-coupled receptors: An evolving history in autoimmunity. Report of the 4th international symposium

Otávio Cabral-Marques^*, Guido Moll, Rusan Catar, Beate Preuß, Lukas Bankamp, Ann Christin Pecher, Joerg Henes, Reinhild Klein, A. S. Kamalanathan, Reza Akbarzadeh, Wieke van Oostveen, Bettina Hohberger, Matthias Endres, Bryan Koolmoes, Nivine Levarht, Rudmer Postma, Vincent van Duinen, Anton Jan van Zonneveld, Jeska de Vries-Bouwstra, Cynthia FehresFlorian Tran, Fernando Yuri Nery do Vale, Kamilla Batista da Silva Souza, Igor Salerno Filgueiras, Lena F. Schimke, Gabriela Crispim Baiocchi, Gustavo Cabral de Miranda, Dennyson Leandro Mathias da Fonseca, Paula Paccielli Freire, Alexander M. Hackel, Hanna Grasshoff, Anja Kerstein-Stähle, Antje Müller, Ralf Dechend, Xinhua Yu, Frank Petersen, Franziska Sotzny, Thomas P. Sakmar, Hans D. Ochs, Kai Schulze-Forster, Harald Heidecke, Carmen Scheibenbogen, Yehuda Shoenfeld, Gabriela Riemekasten^*

^*Corresponding author for this work

Department of Rheumatology and Clinical Immunology

35 Citations (Scopus)

Abstract

G protein-coupled receptors (GPCR) are involved in various physiological and pathophysiological processes. Functional autoantibodies targeting GPCRs have been associated with multiple disease manifestations in this context. Here we summarize and discuss the relevant findings and concepts presented in the biennial International Meeting on autoantibodies targeting GPCRs (the 4th Symposium), held in Lübeck, Germany, 15–16 September 2022. The symposium focused on the current knowledge of these autoantibodies' role in various diseases, such as cardiovascular, renal, infectious (COVID-19), and autoimmune diseases (e.g., systemic sclerosis and systemic lupus erythematosus). Beyond their association with disease phenotypes, intense research related to the mechanistic action of these autoantibodies on immune regulation and pathogenesis has been developed, underscoring the role of autoantibodies targeting GPCRs on disease outcomes and etiopathogenesis. The observation repeatedly highlighted that autoantibodies targeting GPCRs could also be present in healthy individuals, suggesting that anti-GPCR autoantibodies play a physiologic role in modeling the course of diseases. Since numerous therapies targeting GPCRs have been developed, including small molecules and monoclonal antibodies designed for treating cancer, infections, metabolic disorders, or inflammatory conditions, anti-GPCR autoantibodies themselves can serve as therapeutic targets to reduce patients' morbidity and mortality, representing a new area for the development of novel therapeutic interventions.

Original language	English
Article number	103310
Journal	Autoimmunity Reviews
Volume	22
Issue number	5
Pages (from-to)	103310
ISSN	1568-9972
DOIs	https://doi.org/10.1016/j.autrev.2023.103310
Publication status	Published - 05.2023

Funding

We thank the São Paulo State Research Support Foundation (FAPESP grants: 2018/18886-9, 2020/01688-0, and 2020/07069-0 to OCM, 2019/14526-0 and 2020/05146-7 to GCM, 2020/09146 to PPF, 2020/16246-2 to DLMF, and 2020/07972-1 to GCB). This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – Brasil (CAPES) – Finance Code 001, Grants to KBSS and FYNV. We acknoledge the National Council for Scientific and Technological Development (CNPq) , Brazil (grants: 309482/2022-4 to OCM and to 102430/2022-5 to LFS) G.M.'s contributions were made possible by the German Research Foundation / Deutsche Forschungsgemeinschaft (DFG; EXPAND-PD CA2816/1-1) and German Federal Ministry of Education and Research (BMBF) funding through the BSRT (GSC203) and BCRT. In addition, this project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreements No 733006 (PACE) and No 779293 (HIPGEN). Contributions of R.C. were made possible by funding from the DFG project #394046635, subproject A03, as part of CRC 1365 and EXPAND-PD; CA2816/1-1. Furthermore, GR, HG, and FT received funding from the excellence cluster precision medicine in chronic inflammation, Mesinflame funding to GR, and IMMME funding to GR, CS, and FS. Funding by the BMBF, German Center for Lung Research (DZL), and by the DFG RTG 2633 “Autoimmune Pre-Disease”; Project B3 enabled contributions by X.Y. and F.P. We acknowledge all sponsors of the 4th RAB Symposium in Lübeck: Deutsche Forschungsgemeinschaft (DFG), CellTrend, Abbvie, Galápagos, Janssen Pharmaceutical Companies, AstraZeneca, Boehringer Ingelheim, Biogen, Bristol Myers Squibb, EUROIMMUN, GlaxoSmithKline (GSK), and UCB Biopharma.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research Areas and Centers

Academic Focus: Center for Infection and Inflammation Research (ZIEL)

Access to Document

10.1016/j.autrev.2023.103310

Cite this

Cabral-Marques, O., Moll, G., Catar, R., Preuß, B., Bankamp, L., Pecher, A. C., Henes, J., Klein, R., Kamalanathan, A. S., Akbarzadeh, R., van Oostveen, W., Hohberger, B., Endres, M., Koolmoes, B., Levarht, N., Postma, R., van Duinen, V., van Zonneveld, A. J., de Vries-Bouwstra, J., ... Riemekasten, G. (2023). Autoantibodies targeting G protein-coupled receptors: An evolving history in autoimmunity. Report of the 4th international symposium. Autoimmunity Reviews, 22(5), 103310. Article 103310. https://doi.org/10.1016/j.autrev.2023.103310

@article{d6d469a3b03e45ebaa68d7eb52a0585b,

title = "Autoantibodies targeting G protein-coupled receptors: An evolving history in autoimmunity. Report of the 4th international symposium",

abstract = "G protein-coupled receptors (GPCR) are involved in various physiological and pathophysiological processes. Functional autoantibodies targeting GPCRs have been associated with multiple disease manifestations in this context. Here we summarize and discuss the relevant findings and concepts presented in the biennial International Meeting on autoantibodies targeting GPCRs (the 4th Symposium), held in L{\"u}beck, Germany, 15–16 September 2022. The symposium focused on the current knowledge of these autoantibodies' role in various diseases, such as cardiovascular, renal, infectious (COVID-19), and autoimmune diseases (e.g., systemic sclerosis and systemic lupus erythematosus). Beyond their association with disease phenotypes, intense research related to the mechanistic action of these autoantibodies on immune regulation and pathogenesis has been developed, underscoring the role of autoantibodies targeting GPCRs on disease outcomes and etiopathogenesis. The observation repeatedly highlighted that autoantibodies targeting GPCRs could also be present in healthy individuals, suggesting that anti-GPCR autoantibodies play a physiologic role in modeling the course of diseases. Since numerous therapies targeting GPCRs have been developed, including small molecules and monoclonal antibodies designed for treating cancer, infections, metabolic disorders, or inflammatory conditions, anti-GPCR autoantibodies themselves can serve as therapeutic targets to reduce patients' morbidity and mortality, representing a new area for the development of novel therapeutic interventions.",

author = "Ot{\'a}vio Cabral-Marques and Guido Moll and Rusan Catar and Beate Preu{\ss} and Lukas Bankamp and Pecher, \{Ann Christin\} and Joerg Henes and Reinhild Klein and Kamalanathan, \{A. S.\} and Reza Akbarzadeh and \{van Oostveen\}, Wieke and Bettina Hohberger and Matthias Endres and Bryan Koolmoes and Nivine Levarht and Rudmer Postma and \{van Duinen\}, Vincent and \{van Zonneveld\}, \{Anton Jan\} and \{de Vries-Bouwstra\}, Jeska and Cynthia Fehres and Florian Tran and \{do Vale\}, \{Fernando Yuri Nery\} and \{da Silva Souza\}, \{Kamilla Batista\} and Filgueiras, \{Igor Salerno\} and Schimke, \{Lena F.\} and Baiocchi, \{Gabriela Crispim\} and \{de Miranda\}, \{Gustavo Cabral\} and \{da Fonseca\}, \{Dennyson Leandro Mathias\} and Freire, \{Paula Paccielli\} and Hackel, \{Alexander M.\} and Hanna Grasshoff and Anja Kerstein-St{\"a}hle and Antje M{\"u}ller and Ralf Dechend and Xinhua Yu and Frank Petersen and Franziska Sotzny and Sakmar, \{Thomas P.\} and Ochs, \{Hans D.\} and Kai Schulze-Forster and Harald Heidecke and Carmen Scheibenbogen and Yehuda Shoenfeld and Gabriela Riemekasten",

note = "Publisher Copyright: {\textcopyright} 2023",

year = "2023",

month = may,

doi = "10.1016/j.autrev.2023.103310",

language = "English",

volume = "22",

pages = "103310",

journal = "Autoimmunity Reviews",

issn = "1568-9972",

publisher = "Elsevier B.V.",

number = "5",

}

Cabral-Marques, O, Moll, G, Catar, R, Preuß, B, Bankamp, L, Pecher, AC, Henes, J, Klein, R, Kamalanathan, AS, Akbarzadeh, R, van Oostveen, W, Hohberger, B, Endres, M, Koolmoes, B, Levarht, N, Postma, R, van Duinen, V, van Zonneveld, AJ, de Vries-Bouwstra, J, Fehres, C, Tran, F, do Vale, FYN, da Silva Souza, KB, Filgueiras, IS, Schimke, LF, Baiocchi, GC, de Miranda, GC, da Fonseca, DLM, Freire, PP, Hackel, AM , Grasshoff, H , Kerstein-Stähle, A , Müller, A, Dechend, R, Yu, X, Petersen, F, Sotzny, F, Sakmar, TP, Ochs, HD, Schulze-Forster, K, Heidecke, H, Scheibenbogen, C, Shoenfeld, Y & Riemekasten, G 2023, 'Autoantibodies targeting G protein-coupled receptors: An evolving history in autoimmunity. Report of the 4th international symposium', Autoimmunity Reviews, vol. 22, no. 5, 103310, pp. 103310. https://doi.org/10.1016/j.autrev.2023.103310

TY - JOUR

T1 - Autoantibodies targeting G protein-coupled receptors

T2 - An evolving history in autoimmunity. Report of the 4th international symposium

AU - Cabral-Marques, Otávio

AU - Moll, Guido

AU - Catar, Rusan

AU - Preuß, Beate

AU - Bankamp, Lukas

AU - Pecher, Ann Christin

AU - Henes, Joerg

AU - Klein, Reinhild

AU - Kamalanathan, A. S.

AU - Akbarzadeh, Reza

AU - van Oostveen, Wieke

AU - Hohberger, Bettina

AU - Endres, Matthias

AU - Koolmoes, Bryan

AU - Levarht, Nivine

AU - Postma, Rudmer

AU - van Duinen, Vincent

AU - van Zonneveld, Anton Jan

AU - de Vries-Bouwstra, Jeska

AU - Fehres, Cynthia

AU - Tran, Florian

AU - do Vale, Fernando Yuri Nery

AU - da Silva Souza, Kamilla Batista

AU - Filgueiras, Igor Salerno

AU - Schimke, Lena F.

AU - Baiocchi, Gabriela Crispim

AU - de Miranda, Gustavo Cabral

AU - da Fonseca, Dennyson Leandro Mathias

AU - Freire, Paula Paccielli

AU - Hackel, Alexander M.

AU - Grasshoff, Hanna

AU - Kerstein-Stähle, Anja

AU - Müller, Antje

AU - Dechend, Ralf

AU - Yu, Xinhua

AU - Petersen, Frank

AU - Sotzny, Franziska

AU - Sakmar, Thomas P.

AU - Ochs, Hans D.

AU - Schulze-Forster, Kai

AU - Heidecke, Harald

AU - Scheibenbogen, Carmen

AU - Shoenfeld, Yehuda

AU - Riemekasten, Gabriela

PY - 2023/5

Y1 - 2023/5

N2 - G protein-coupled receptors (GPCR) are involved in various physiological and pathophysiological processes. Functional autoantibodies targeting GPCRs have been associated with multiple disease manifestations in this context. Here we summarize and discuss the relevant findings and concepts presented in the biennial International Meeting on autoantibodies targeting GPCRs (the 4th Symposium), held in Lübeck, Germany, 15–16 September 2022. The symposium focused on the current knowledge of these autoantibodies' role in various diseases, such as cardiovascular, renal, infectious (COVID-19), and autoimmune diseases (e.g., systemic sclerosis and systemic lupus erythematosus). Beyond their association with disease phenotypes, intense research related to the mechanistic action of these autoantibodies on immune regulation and pathogenesis has been developed, underscoring the role of autoantibodies targeting GPCRs on disease outcomes and etiopathogenesis. The observation repeatedly highlighted that autoantibodies targeting GPCRs could also be present in healthy individuals, suggesting that anti-GPCR autoantibodies play a physiologic role in modeling the course of diseases. Since numerous therapies targeting GPCRs have been developed, including small molecules and monoclonal antibodies designed for treating cancer, infections, metabolic disorders, or inflammatory conditions, anti-GPCR autoantibodies themselves can serve as therapeutic targets to reduce patients' morbidity and mortality, representing a new area for the development of novel therapeutic interventions.

AB - G protein-coupled receptors (GPCR) are involved in various physiological and pathophysiological processes. Functional autoantibodies targeting GPCRs have been associated with multiple disease manifestations in this context. Here we summarize and discuss the relevant findings and concepts presented in the biennial International Meeting on autoantibodies targeting GPCRs (the 4th Symposium), held in Lübeck, Germany, 15–16 September 2022. The symposium focused on the current knowledge of these autoantibodies' role in various diseases, such as cardiovascular, renal, infectious (COVID-19), and autoimmune diseases (e.g., systemic sclerosis and systemic lupus erythematosus). Beyond their association with disease phenotypes, intense research related to the mechanistic action of these autoantibodies on immune regulation and pathogenesis has been developed, underscoring the role of autoantibodies targeting GPCRs on disease outcomes and etiopathogenesis. The observation repeatedly highlighted that autoantibodies targeting GPCRs could also be present in healthy individuals, suggesting that anti-GPCR autoantibodies play a physiologic role in modeling the course of diseases. Since numerous therapies targeting GPCRs have been developed, including small molecules and monoclonal antibodies designed for treating cancer, infections, metabolic disorders, or inflammatory conditions, anti-GPCR autoantibodies themselves can serve as therapeutic targets to reduce patients' morbidity and mortality, representing a new area for the development of novel therapeutic interventions.

UR - https://www.scopus.com/pages/publications/85150078492

UR - https://www.mendeley.com/catalogue/f59ca7b3-739e-3568-a0f7-cb4f21955627/

U2 - 10.1016/j.autrev.2023.103310

DO - 10.1016/j.autrev.2023.103310

M3 - Scientific review articles

C2 - 36906052

AN - SCOPUS:85150078492

SN - 1568-9972

VL - 22

SP - 103310

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

IS - 5

M1 - 103310

ER -

Autoantibodies targeting G protein-coupled receptors: An evolving history in autoimmunity. Report of the 4th international symposium

Abstract

Funding

UN SDGs

Research Areas and Centers

Access to Document

Other files and links

Fingerprint

DFG Research Training Group RTG 2633: Defining and Targeting Autoimmune Pre-Disease

Cite this

Autoantibodies targeting G protein-coupled receptors: An evolving history in autoimmunity. Report of the 4th international symposium

Abstract

Funding

UN SDGs

Research Areas and Centers

Access to Document

Other files and links

Fingerprint

Projects

DFG Research Training Group RTG 2633: Defining and Targeting Autoimmune Pre-Disease

Cite this